false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - Advance ...
Nanoparticle and AAV Delivery to the Kidneys
Nanoparticle and AAV Delivery to the Kidneys
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. Michael Berry compared adenovirus, AAV, and lipid nanoparticles (LNPs) as gene-delivery vehicles, emphasizing that no vector is best for every application. Adenoviruses can carry much larger genes than AAVs and often deliver genes more potently, but they are immunogenic and too large to reach many cells efficiently from the bloodstream. AAV and LNP delivery to the kidney also faces substantial barriers, and systemic administration often results in greater delivery to the liver and other off-target tissues.<br /><br />In mouse studies, kidney injury or developing disease increased delivery in some settings, but did not reliably improve targeting of kidney tubules. LNPs carrying mRNAs for the three collagen genes involved in Alport syndrome reduced disease measures, though treatment had to be repeated; disease returned after treatment stopped.<br /><br />Berry described efforts to improve targeting by selecting peptide ligands in the structural context of viral proteins. His team is using a rapid adenovirus-engineering platform to screen large libraries and has identified candidates with increased activity in human podocytes. These early results demonstrate proof of concept, though specificity remains uncertain. The broader goal is to use this approach to discover targeting ligands that can also be transferred to other viral vectors, including AAV.
Asset Caption
Michael A. Barry, PhD
Meta Tag
Speaker
Michael Barry
Keywords
adenovirus
AAV
lipid nanoparticles
gene delivery
kidney targeting
Alport syndrome
podocytes
Michael Barry
×
Please select your language
1
English